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gMyelodysplasia and acute leukemia have been re-
orted after high-dose chemotherapy and autologous
tem cell transplantation [1,2]. Mean corpuscular vol-
me (MCV) elevation after the administration of che-
otherapy and its relationship to the risk of secondary
eukemia are suggested in long-term survivors [3,4].
he incidence and signiﬁcance of MCV elevation af-
er high-dose chemotherapy and autologous hemato-
oietic stem cell transplantation are unknown.
We performed a retrospective analysis of 130 con-
ecutive patients who underwent autologous hemato-
oietic stem cell transplantation between January
999 and December 2003. Patients with relapse of
isease within 6 months of transplantation and those
ith inadequate follow-up were excluded. Sixty-three
48%) of 130 patients (non-Hodgkin lymphoma, n 
0; neuroblastoma, n  16; Hodgkin disease, n  8;
reast cancer, n  8; myeloma, n  7; acute myelog-
nous leukemia, n  2; and testicular cancer, n  2)
ere eligible for analysis. The complete blood count
roﬁle obtained by using an automated Coulter counter
Beckman Coulter, Inc, Fullerton, CA) (and manual
valuation, when available) was analyzed at transplanta-
ion, at 6 months, at 1 year, and yearly after transplan-
ation. Patient characteristics were analyzed, including
ime to achieve engraftment (absolute neutrophil count
500/L and platelet count 20 000/L) and time to
chieve long-term hematological recovery (hemoglobin
12 g/dL, white cell count 4000/L, and platelet
ount 150 000/L). When available, a history of
lcohol abuse, abnormal liver or thyroid function, and
itamin B12 or folate deﬁciency were recorded.
The median age was 41 years (range, 1-76 years).
hirty-seven were men, and 26 were women. All pa-
ients underwent peripheral blood stem cell transplan-
able 1. Mean Corpuscular Volume in Autologous Hematopoietic Stem
MCV Baseline (fL) 6 m
dults (n  43) 97.5 102.7 (rang
hildren (n  20) 90.8 94.1 (rangCV reference range: adults, 81-99 fL; children, 75-87 fL.
B&MTation; 6 patients underwent double autotransplanta-
ion. The median time to engraftment for neutrophils
nd platelets was 12 and 14 days, respectively. The
edian time to long-term hematologic recovery as
eﬁned previously was 289 days; 27 (81%) patients
ad suboptimal hematopoietic recovery at 6 months.
t a median follow-up of 30 months (range, 6-73
onths), 33 (52.8%) of 63 patients displayed increased
CV 6 months after transplantation (Table 1). The
CV increase was observed above reference values at
ll pediatric ages. For children aged 6 months to 5
ears (reference range, 75-87 fL), the mean pretrans-
lantation MCV of 90.8 fL increased to 94 fL. In
hildren aged 6 to 18 years (reference range, 77-95
L), the mean pretransplantation MCV of 90.8 fL
ncreased to 96 fL. Persistent MCV elevation was
bserved in 65% and 50% of patients at 1 and 2 years
fter transplantation, respectively. Further investiga-
ions of macrocytosis in form of liver function tests,
hyroid function tests, vitamin B12 or folate deﬁ-
iency, and history of alcohol abuse had negative re-
ults. MCV elevation was independent of age, disease,
D34 cell dose, conditioning regimen, and number of
ransplantations.
Increased MCV after high-dose therapy and trans-
lantation likely reﬂects injury to the bone marrow
icroenvironment, ineffective erythropoiesis, or both.
previous study with autotransplantation in breast
ancer reported persistently increased MCV in 25%
f transplant recipients [5]. These results were inde-
endent of age, high-dose regimen, number of rein-
used stem cells, and stem cell source. Patients with
ouble (n  12) versus single (n  119) transplanta-
ions showed signiﬁcantly higher MCV. No secondary
raft failure, myelodysplasia, or leukemia was encoun-
ransplant Recipients
1 y (fL) Incidence
-11.2) 101.3 (range, 92.5-105) 15/43 (35%)
-104) 97.3 (range, 78.7-100) 18/20 (91%)Cell T
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1ered [5]. Our results reﬂect a higher incidence of
acrocytosis. Additionally, we provide results in pe-
iatric transplant recipients.
Persistent elevation of MCV without development
f anemia or overt myelodysplasia is common after
utologous transplantation, with an incidence of ap-
roximately 50%. Long-term follow-up is needed to
etermine its signiﬁcance (if any).
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